Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics, Inc. centers on allegations that the company misrepresented the clinical efficacy of its product SLK compared to traditional monoclonal antibodies, particularly BIMZELX, leading to significant investor losses [2][3]. Legal Allegations - The lawsuit claims that MoonLake failed to disclose that SLK and BIMZELX share the same molecular targets (interleukin-17, or IL-17), which undermines the claimed competitive advantage of SLK [3]. - Allegations include that MoonLake misrepresented the Nanobody structure's ability to provide superior clinical efficacy, specifically in treating hidradenitis suppurativa (HS) [3]. - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these issues [3]. Investor Actions - Hagens Berman is actively advising investors who purchased MLTX shares during the Class Period (March 10, 2024, through September 29, 2025) and suffered substantial losses due to the alleged undisclosed trial flaws [4]. - The deadline for investors to move the Court for appointment as lead plaintiff in the securities class action lawsuit is December 15, 2025 [1][4]. Firm Background - Hagens Berman is a global plaintiffs' rights law firm that has secured over $2.9 billion in settlements for investors in similar cases [4][8].